Share Prices & Company Research

Market News

10 Nov 2020 | 13:45

Croda secures vaccine contract with Pfizer

(Sharecast News) - Specialty chemical company Croda International said on Tuesday that it has entered into an agreement with US-based Pfizer to supply novel excipients used in the manufacture of a Covid-19 vaccine candidate. Set to run for five years, the agreement awards Croda an initial supply contract for four component excipients used in the production of the vaccine candidate for the first three years of the contract.

Demand remains subject to relevant approvals, Croda said.

Chief executive officer Steve Foots said: "I'm very proud of Croda's involvement in the battle to fight the most significant pandemic that we have seen in a generation. The application of our innovative capabilities is testament to the strong progress we have made to create industry-leading drug delivery systems, focused on developing speciality excipients and adjuvants to improve the effectiveness and stability of complex drug actives and vaccines."

Croda shares shot higher on the news and by 1400 GMT, were trading up 6.5% at 6,624p.

Pfizer announced on Monday that the Covid-19 vaccine it is developing with BioNTech had shown 90% efficacy in interim analysis.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 15th January 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.